Butizide

Clinical data
Other names	thiabutazide, buthiazide
ATC code	C03EA14 (WHO) (combination with potassium-sparing diuretics)
Pharmacokinetic data
Bioavailability	85%
Protein binding	60–80%
Metabolism	hepatic
Elimination half-life	4 hours
Excretion	30% unchanged with the urine
Identifiers
CAS Number	2043-38-1
PubChem CID	16274
ChemSpider	15442 Y
UNII	W00SSD35VW
KEGG	D03189
CompTox Dashboard (EPA)	DTXSID6022713
ECHA InfoCard	100.016.409
Chemical and physical data
Formula	C11H16ClN3O4S2
Molar mass	353.84 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)CC1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
InChI InChI=1S/C11H16ClN3O4S2/c1-6(2)3-11-14-8-4-7(12)9(20(13,16)17)5-10(8)21(18,19)15-11/h4-6,11,14-15H,3H2,1-2H3,(H2,13,16,17) Y Key:HGBFRHCDYZJRAO-UHFFFAOYSA-N Y

Butizide (or thiabutazide) is a diuretic of the thiazide class.^[1]

Butizide is used in combination with the potassium-sparing diuretic spironolactone for the second-line treatment of edema caused by heart failure, and for difficult cases of hypertension.^[1]

The hypotensive effects of butizide can be increased by antihypertensive drugs (especially ACE inhibitors), barbiturates, tricyclic antidepressants, and ethanol. Combinatino with beta blockers can increase blood glucose levels; and conversely, butizide can decrease the effects of antidiabetic drugs. As butizide lowers blood potassium and magnesium levels, it can increase the effects of cardiac glycosides. It can also increase lithium toxicity.^[1]

Nonsteroidal anti-inflammatory drugs can decrease the diuretic effect of butizide.^[1]

Butizide is quickly absorbed from the gut with a bioavailability of 85%. It reaches highest blood plasma concentrations after 2.5 hours. Plasma protein binding is 60 to 80%. While the substance is metabolised in the liver, 30% are excreted in unchanged from with the urine. Elimination half-life is about four hours.^[1]